http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Horizon Pharma plc Named One of the Best Small & Medium Workplaces by FORTUNE and Great Place to Work® for the Second Year in a Row
-
Horizon Pharma plc to Host Third-Quarter 2017 Conference Call and Webcast on Nov. 6, 2017
-
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Horizon Pharma plc Names Irina Konstantinovsky Executive Vice President, Chief Human Resources Officer
-
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Horizon Pharma plc to Participate in Morgan Stanley 15th Annual Global Healthcare Conference
-
Horizon Pharma plc Announces Second-Quarter and Year-to-Date 2017 Results and Increases Full-Year 2017 Net Sales and Adjusted EBITDA Guidance
-
Horizon Pharma plc Appoints Pascale Witz and James Shannon, M.D. to Board of Directors
-
Horizon Pharma plc Launches CGD Connections™ to Deliver Support and Resources Created by and for the Chronic Granulomatous Disease (CGD) Community
-
Horizon Pharma plc Announces Four Poster Presentations on PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Capsules at Cystinosis Research Network 2017 Family Conference
-
Horizon Pharma plc to Host Second-Quarter 2017 Conference Call and Webcast on Aug. 7, 2017
-
Horizon Pharma plc Announces District Court Decision to Uphold VIMOVO® (naproxen/esomeprazole magnesium) Patents
-
Horizon Pharma plc Completes Sale of European Marketing Rights for PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin nebuliser solution) in Europe, Middle East
-
Horizon Pharma plc Partners with Global Genes® to Unite the Rare Disease Community at the Biotechnology Innovation Organization (BIO) International Convention
-
Horizon Pharma plc Announces Health Canada Approval of PROCYSBI™ (Cysteamine Delayed-Release Capsules) for the Treatment of Nephropathic Cystinosis
-
Horizon Pharma (HZNP) Presents Data Analyses Showing Clinical Benefit of KRYSTEXXA in Patients with Uncontrolled Gout
-
Horizon Pharma plc Presents New Data Analyses Further Demonstrating Clinical Benefit of KRYSTEXXA® (pegloticase) in Patients with Uncontrolled Gout
-
Epidemiologic Study Findings Show Over 400 Percent Increase in Gout Patient Hospitalizations Since 1993
-
Horizon Pharma plc Completes Acquisition of Raptor Pharmaceutical Corp.
-
Horizon Pharma plc Named One of the Country's Best Medium Workplaces by Fortune Magazine
-
Horizon Pharma plc to Host Third-Quarter 2016 Conference Call and Webcast on November 7, 2016
-
Horizon Pharma (HZNP) Enters Rebate Agreement with Prime Therapeutics
-
Horizon Pharma plc Provides Update on PBM Formulary Status for Primary Care Medicines
-
Horizon Pharma plc to Acquire Raptor Pharmaceutical Corp. as Further Step in Building Leading Rare Disease Business
-
Horizon Pharma plc to Participate in Morgan Stanley Global Healthcare Conference
-
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering RAYOS® (prednisone) Delayed-Release Tablets
-
Horizon Pharma plc Announces Second-Quarter 2016 Financial Results
-
Horizon Pharma plc to Host Second-Quarter 2016 Conference Call and Webcast on August 8, 2016
-
Horizon Pharma (HZNP) Announces Submission of RAVICTI sNDA o Expand Age Range for Management of Urea Cycle Disorders
-
Horizon Pharma plc Submits Supplemental New Drug Application for RAVICTI(R) (glycerol phenylbutyrate) Oral Liquid to Expand Age Range for Management of Urea Cycle Disorders
-
Horizon Pharma plc Added to Russell 2000(R) and 3000(R) Indexes
-
Horizon Pharma plc to Participate in Jefferies 2016 Healthcare Conference
-
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO(R) (naproxen/esomeprazole) Delayed Release Tablets
-
Horizon Pharma plc to Acquire Worldwide Rights to Interferon Gamma-1b From Boehringer Ingelheim International GmbH
-
Horizon Pharma plc to Participate in UBS Global Healthcare Conference
-
Horizon Pharma plc Announces That Marilyn Vetter Honored as a 2016 Healthcare Businesswomen's Association Luminary
-
Horizon Pharma (HZNP) Settles PENNSAID Patent Dispute
-
Horizon Pharma plc Announces Settlement of PENNSAID(R) (diclofenac sodium topical solution) 2% w/w Patent Litigation With Teligent, Inc.
-
Horizon Pharma (HZNP) Receives USPTO Notice of Allowance for KRYSTEXXA-Related Patent
-
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notice of Allowance With Claims Covering KRYSTEXXA(R) (pegloticase)
-
Horizon Pharma plc Announces First-Quarter 2016 Financial Results
-
Horizon Pharma (HZNP) Completes Target Enrollment of 90 Patients for Phase 3 Trial of ACTIMMUNE
-
Horizon Pharma plc Completes Target Enrollment of 90 Patients for Phase 3 Trial of ACTIMMUNE(R) (interferon gamma-1b) for the Treatment of People With Friedreich's Ataxia
-
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Three Additional Notices of Allowance With Claims Covering PENNSAID(R) (diclofenac sodium topical solution) 2% w/w
-
Horizon Pharma plc to Present at Two Investor Conferences in May
-
Horizon Pharma plc Announces Settlement of PENNSAID(R) (diclofenac sodium topical solution) 2% w/w Patent Litigation With Amneal Pharmaceuticals LLC
-
Horizon Pharma plc to Host First-Quarter 2016 Conference Call and Webcast on May 9, 2016
-
Horizon Pharma plc Named to Crain's Chicago Business First Ever 2016 "Best Places To Work for Women Over 35" List
-
Horizon Pharma (HZNP) Receives Approval in Canada for RAVICTI as Urea Cycle Disorders Treatment
